Neuregulin Signaling Control for Cardiomyocyte Subtype Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for cardiac repair and pacemaker development face challenges in differentiating stem cells into specific cardiac subtypes for effective transplantation, leading to inadequate integration and increased risk of arrhythmogenesis.
Innovation Solution
A method involving culturing stem cells to produce cardiomyocytes and using antagonists of neuregulin-1 or ErbB to induce nodal/pacemaker phenotypes, and agonists of neuregulin-1 or ErbB receptors to induce atrial/ventricular phenotypes, resulting in isolated populations of cardiomyocytes with specific electrophysiological and molecular characteristics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If stem cells are differentiated into cardiomyocytes using conventional methods, then cardiomyocyte production is achieved, but the subtype specificity is insufficient leading to inadequate integration and increased arrhythmogenic risk
Solution Approach 1:
The patent applies parameter changes by manipulating neuregulin-1/ErbB signaling pathway parameters (agonist/antagonist treatment) to control cardiomyocyte differentiation into specific subtypes. This resolves the contradiction by enabling precise control over cell fate decisions, producing homogeneous populations of either nodal/pacemaker or atrial/ventricular cardiomyocytes, thereby improving both manufacturing precision and integration reliability while reducing arrhythmogenic risks
2Productivity
If stem cells are differentiated without neuregulin signaling manipulation, then general cardiomyocyte production is achieved, but enriched populations of specific cardiac subtypes cannot be obtained
Solution Approach 1:
By changing the parameters of neuregulin-1/ErbB signaling (introducing agonists or antagonists during differentiation), the patent simultaneously achieves high productivity of enriched cardiomyocyte populations and high manufacturing precision of specific cardiac subtypes. The signaling manipulation acts as a control parameter that directs differentiation efficiency toward desired cell fates
Solution Approach 2:
The neuregulin-1/ErbB signaling pathway serves as an intermediary mechanism that mediates the differentiation process. By introducing agonists or antagonists as intermediaries, the patent enables controlled production of enriched cardiomyocyte populations with specific phenotypes, resolving both productivity and precision requirements
Data Source
AI summary
The present invention is directed to methods of producing cardiomyocytes having a nodal/pacemaker phenotype and cardiomyocytes having an atrial/ventricular phenotype. Isolated populations of nodal/pacemaker and atrial/ventricular cardiomyocytes are also disclosed. Methods of treating a subject having cardiac arrhythmia and a subject in need of cardiac tissue repair using the isolated populations of nodal/pacemaker cardiomyocytes and atrial/ventricular cardiomyocytes, receptively, are also disclosed.